e-therapeutics plc (ETXPF)
- Previous Close
0.0000 - Open
0.1300 - Bid --
- Ask --
- Day's Range
0.1300 - 0.1300 - 52 Week Range
0.1300 - 0.1300 - Volume
10,030 - Avg. Volume
0 - Market Cap (intraday)
75.964M - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. The company offers HepNet, a hepatocyte-focused computational platform that enables identification of novel gene targets, improves drug design, and increases automation; and GalOmic, RNA interference (RNAi) platform that generates potent and safe GalNAc-siRNA therapeutics to selectively silence novel disease-associated genes in hepatocytes. Its preclinical products are ETX-312 to treat metabolic dysfunction-associated steatohepatitis; and ETX-407 for the treatment of dry age-related macular degeneration. The company also develops ETX-148 for haemophilia; ETX-291 to treat cardiometabolic disease, ETX-258 for heart failure; and ETX-394 to treat metabolic dysfunction-associated steatohepatitis. e-therapeutics plc incorporated in 2001 and is based in London, the United Kingdom.
www.etherapeutics.co.ukRecent News: ETXPF
View More
Performance Overview: ETXPF
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ETXPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ETXPF
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.75%
Return on Equity (ttm)
-32.78%
Revenue (ttm)
158k
Net Income Avi to Common (ttm)
-11.83M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
41.04M
Total Debt/Equity (mrq)
1.17%
Levered Free Cash Flow (ttm)
-9.57M